| Nov 20 |
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
|
| Nov 19 |
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
|
| Nov 19 |
Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley
|
| Nov 14 |
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
|
| Nov 13 |
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
|
| Nov 9 |
Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript
|
| Nov 9 |
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Nov 8 |
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
|
| Nov 8 |
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...
|
| Nov 7 |
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics
|
